1. LON-CAPA Logo
  2. Help
  3. Log In
 

Resources About Us What's New Notice Board Opinion FAQ Archive Feedback Main
Curricula
Discussion Papers
Handbooks
Lessons Learned
Methods manuals
Regional Activities
Research Techniques
Videos
Working Papers
 
4. The Issues Involved

Collecting programmes raise issues of two kinds. First, there are ethical and legal issues relating to intellectual property rights and the use of indigenous knowledge. Second, there are conservation issues, such as avoiding overexploitation and assisting the justification of conservation as a form of land use through channeling the value-added benefits arising from natural product development into appropriate areas. Encouragingly, a number of professional societies, national research organizations, and international agencies have taken resolutions, or drafted codes of ethics, to deal with one or both of these kinds of issue.

4.1 Ethical and Legal Approaches

Neither ethnobotany nor anthropology are purely academic pursuits. Researchers working with traditional specialists such as herbalists are not only in a position of trust at the interface between cultures, they are at the «sharp end» of industrial society, gathering and publishing data on useful wild plants. Ethnobotanists in particular are in a pivotal position, and raise many ethical questions, e.g. should the private knowledge of community specialists be made public free of charge or at a price? In many cases, such knowledge is only obtained from traditional specialists within a community after the ethnobotanist has established credibility within that society and with the specialists concerned. Detailed information can often only be obtained after an extended period. Researchers often have to earn a position of trust in order to record information that may be shielded from other members of the community by initiation rites and taboos. How far does that position of trust extend? Purchase of information is often not practical for it can tempt respondents into giving nonsense answers for material gain. Alternative means of compensation must be considered.

4.1.1 Views of indigenous peoples

Indigenous peoples striving to maintain the integrity of their cultures are very aware of the changes being brought about by outside technologies. Also recognized are the potential material and social benefits that some developments can bring, but, rather than be passive victims of change, there is preference for partnerships in this process. Recognition of intellectual property is one form of recognition in such a partnership.

At a meeting in Penang, Malaysia, in 1992, representatives of indigenous peoples drafted a «Charter of the Indigenous Tribal Peoples of the Tropical Forests». This was in response to the threats of encroachment and forest destruction they faced. The Charter stressed the social, spiritual, and cultural values of forests in addition to their economic value, and called for the several actions that particularly relate to ethics, biodiversity, and the development of new natural products. The Charter includes the following requests:

...all policies towards the forests must be based on respect for cultural diversity, for promotion of indigenous models of living, and an understanding that our peoples have developed ways of life closely attuned to their environment (Article 5)

...the right to be informed, consulted and, above all, to participate in decision-making on legislation and policies, and in the formulation, implementation or evaluation of any development project, whether local, national or international, private or of the state, that may affect our futures directly or indirectly (Article 23)

…promotion of the health systems of the indigenous peoples, including the revalidation of traditional medicine, and the promotion of programmes of modern medicine and primary healthcare. Such programmes should allow us to have control over them, providing suitable training to allow us to manage them ourselves (Article 31)

...promotion of alternative fiscal policies that permit us to develop our community economies and develop mechanisms to establish fair prices for the products of our forests (Article 33)

...programmes related to biodiversity must respect the collective right of our peoples to cultural and intellectual property, genetic resources, gene banks, biotechnology, and knowledge of biodiversity; this should include our participation in the management of any such project on our territories, as well as control of benefits that derive from them (Article 40)

...since we highly value our traditional technologies and believe that our biotechnologies can make important contributions to humanity, including "developed" countries, we demand guaranteed rights to our intellectual property, and control over the development and manipulation of this knowledge (Article 44)

...all investigations in our territories should be carried out with our consent and under joint control and guidance according to mutual agreement, including provision for training, publication and support for indigenous institutions necessary to achieve such control (Article 45).

4.1.2 Customary law, traditional medicine, and intellectual property

Rights of passage and various taboos are a feature of most societies, providing a means of upholding cultural systems through particular values and codes of behaviour. This applies particularly strongly amongst traditional healers due to their important social, religious and healing roles. Consequently, these taboos often also apply to the plants, animals, or ritual objects that provide potent medicines or religious symbols within societies. Taboos on the use or misuse of these items are recognized in customary law. In southern Africa, for example, control over access to powerful medicines is widespread. Taboos placed on powerful medicines are a means of maintaining survival of traditional leadership through control of religious/supernatural power in conjunction with traditional healers.

In a similar sense, the secular authority of the chief is maintained through his position in the designation of land for settlement and food production. It is therefore not surprising to find that customary restrictions on killing strongly symbolic animals such as crocodiles and ground hornbills are widespread in southern Africa, and are recognized as a basis for restricted use today (Cunningham and Zondi, 1992).21 Accidental killing of a ground hornbill necessitates the sacrifice of a beast in traditional Xhosa society (Vernon, 1986),68 or ritual purification after a period of eating and sleeping alone in traditional KwaNyama-Owambo society in Namibia (Rodin, 1985).61

Many traditional healers in southern Africa take the view that some traditional knowledge should not be made freely available. Even within their own societies, much of this specialist knowledge is kept private, rather than public, through ritual and taboo (M.P. Cele, pers comm.). On the other hand, other traditional healers recognize that their knowledge has a wider value and want part of the benefits arising from its use. Why shouldn't they?

Fiona Walsh, an ethnobotanist at the University of Western Australia, has encountered cases in her work with Martu aboriginals where people specifically chose to censor the research information after it had been recorded (F. Walsh, pers comm., 1992). No restrictions were placed on information on widespread useful species, but in some cases she was asked not to tell anyone else about a medicinal plant species or find out its «whitefella» name as the Martu did not want outsiders using the plant or making money from the medicine. There was also concern that inexperienced people should not be exposed to powerful medicines for their own safety. In other cases Martu people requested that vernacular names of localized plants they used were not published. If «whitefellas» wanted to find these plants in Martu country, they would have to work through the Martu people. Similar views have been are expressed by indigenous peoples in other parts of the world.

4.1.3 Fair deals or no deals

Even in remote areas, there is widespread awareness amongst indigenous peoples of the link between traditional and pharmaceutical medicines. There is also awareness of the interest of industrial companies in developing new drugs from plants, and of the commercial values attached to crop genetic resources. There are two good examples of this in Africa: medicinal plants and coffee varieties.

Figure 4. The sales of anti-leukaemia drugs derived from the Madagascar rosy periwinkle (Catharanthus roseus) have generated large profits for the pharmaceutical company Eli-Lilly. Although native to Madagascar, it is now a widespread weed in the tropics and sub-tropics. The sample material for original screening came from the Philippines and Jamaica. A relatively long-lived patent on the active ingredients was taken out for the pure compounds from the plant, which differs from low-cost imitations.
Photo: A.B. Cunningham
Over a decade ago, the Organization of African Unity (OAU) went so far as to urge secrecy in research in herbal medicine in order to prevent multinational companies developing new drugs and selling them back to developing countries at high prices (Hanlon, 1979).34 In Ethiopia, which is a centre of coffee diversity, there are severe restrictions on the collection of plant genetic material. The rationale is understandable, as the genetic resources of Ethiopia should be recognized as a resource of great value to world agriculture. What also needs to be recognized, however, is that prolonged war and economic decline mean that neither habitats nor species can effectively be conserved. Cultural change and the effects of political turmoil speed up the loss of indigenous knowledge. If neither indigenous knowledge nor biodiversity can be conserved, the result is a double tragedy in which everybody loses. This can be prevented through consultation and development of accepted guidelines for researchers. In Panama, for example, Kuna people working together with researchers have established guidelines for cooperative work (Box 1).

A further example is the healthcare and forest conservation initiative which has been developed with local communities, university scientists and doctors through a WWF conservation programme for Manongarivo Special Reserve, Madagascar (Box 2), which includes the development of a role for an ethical pharmaceutical company. Where industrial products are involved, the responsibility for resolving these problems rests not only on the professional ethics of researchers, but also on the policies of governments and organizations sponsoring the collection of biological material. The participation of indigenous peoples in making decisions that relate to their intellectual property or natural resources can be seen as a basic human right. This has already been recognized in the Human Rights section of the US Government Foreign Operations bill (US Government, 1993).67

1..CASE STUDY: PROJECT FOR THE STUDY OF THE MANAGEMENT OF WILDLIFE AREAS OF KUNA YALA (PEMASKY), PANAMA*

This project has aimed at the management of a 60,000ha forest reserve within Kuna land in Panama. It was established by the Kuna Indian people in 1983, with substantial international funding and the support of the Smithsonian Tropi cal Research Institute (STRI).

Research is carried out by non-Kuna scientists working with Kuna assistants. The STRI, based in Panama City, has played an important role in ensuring that research permission is first obtained by scientists and that research reports, photographs and biological specimens are left with the PEMASKY project.

In 1988, the Kuna produced a 26-page manual Research program: Scientific Monitoring and Cooperation, with guidelines and information for visiting researchers. This gave detailed information on how to apply for permission to visit the area, which sites are off-limits and how various activities such as plant collecting and marking of animals are viewed. The manual sets guidelines without being overly bureaucratic, stating for example, that:

All researchers should consider the incorporation of Kuna co-researchers, assistants, guides, and informants, with the objective of training Kuna scientists, and achieving a transfer of knowledge and technologies... The principal researcher will consider paying his assistants and other (local) informants.

Guidelines for feedback from research carried out in the area are also specified, stating that:

Each researcher is asked to send two copies of his publication on the research carried out... if possible, summaries of abstracts should be translated into Spanish

This approach offers an opportunity for benefits to both researchers and research partners.

* Chapin, 19911

 
2. HEALTHCARE, CONSERVATION, AND MEDICINAL PLANTS IN MADAGASCAR

The central ethic of this project is that all those who gain from the use of biodiversity have a responsibility to those who conserve it. Started by Dr Nat Quansah of WWF-Madagascar in 1989, the project set out to determine the links between local communities and local plant diversity, and to evaluate local plants. The link between biological and cultural diversity is a key element in the search for new development options to ensure sustainable use of plant resources. In this process, the aim is not to replace but to legitimize and authenticate the social and environmental fabric of rural society. The main field site is the 35,000ha Manongarivo Special Reserve in northwest Madagascar, a forest area of high biological diversity.

Consultation with local villagers showed that there were three principal community concerns. The most important of these was health. The nearest clinic was 80km away, with a third of this journey made on foot. Drugs in the clinic were very expensive. The second concern was that the road into the area was in poor condition, resulting in high commodity prices for goods brought in, and difficulty in transporting agricultural produce out. The third concern was caused by the local agricultural system of dry-land rice cultivation. This involved a forest slash-and-bum rotation of 5-10 years and threatened eventual total destruction.

It was decided that the project should concentrate initially on health, as this was the principal local

concern, and because medicinal plants, primarily from the forest, are widely used. Through interaction between the community and researchers, the idea emerged of developing an integrated healthcare system, based on traditional remedies supported by modern medicines in cases where necessary. Field teams comprise traditional specialists, ethnobotanists, and doctors. Pharmacologists then test the toxicity of plant extracts and pass the results back to the field team for discussion with the community. The possibility of involving an ethical pharmaceutical company is also being considered as a means of adding value to biodiversity and generating returns to the community. Joint work between the researchers and the community has recently resulted in the construction of a local integrated healthcare clinic, using local design and materials as far as possible. When completed, patients will be attended to by medical doctors and traditional healers, and it is hoped that through good record-keeping it will be possible to build up information on the effectiveness of traditional herbal remedies.

To date, the project has played a central role in training eight Malagasy students, including two PhD graduates in chemistry and four MSc graduates who are pharmacologists or botanists. Ten additional students are undergoing post-graduate training. Two medical doctors and 26 medical students work with the project. All of these students are from the University of Antananarivo.

*Hamilton, pers comm., 1993

4.1.4 Patent rights, biotechnology, and biological material

In an industrial society, if a private company accumulates unique, useful knowledge through trial and error, that knowledge is likely to be patented so that the company obtains a percentage of profits arising from its use. For over a century, ethnobotanists have recorded traditional knowledge, much of which relates to medicinal plants. Such knowledge has also been accumulated in traditional societies by trial and error, but has been made public with no patent rights attached.

Active ingredients of traditional medicines, dyes, fish toxins, fungicides, and insecticides represent novel biological compounds that can be characterized and usually replicated. The discovery of plant species with active ingredients that serve a particular purpose is certainly an inventive, intellectual process. A good example of this is the selection by trial and error of a number of plant species to be combined in a medicinal recipe for their synergistic effect. The selection process can take place in vegetation which may contain hundreds of plant species. Sampling based on traditional knowledge cuts time and costs through providing a short-cut for therapeutic compounds (Box 3). Pure natural compounds, such as vincristine from the rosy periwinkle (Catharanthus roseus) can be patented (Figure 4). In most cases, however, biological material provides the template for development and subsequent synthesis of active compounds. In this case, process patents are granted for new uses of altered compounds derived from the precursor rather than for the naturally occurring compounds themselves.

In an excellent and detailed review of equitable patent protection and developing countries (1991),44 Lesser doubts the appropriateness of applying uniform patent standards to very different circumstances in various developing countries. While it is important to recognize the intellectual contribution made by indigenous peoples to new natural products development, it is also important that countries are free to decide whether to adopt intellectual property protection for biological products like genes and chemical compounds, and how strong that protection should be (WRI, 1992).70 The strength of intellectual property rights (IPR) will depend on the level of technological and industrial development in different developing countries. This has been a crucial issue in the Uruguay round of GATT negotiations, with industrialized countries pushing for uniform patent standards in all countries (Lesser, 1991; WRI, 1992).44,70

Developing countries with a high level of expertise in natural products chemistry, such as Brazil, Mexico, India, Taiwan, and Korea, have the capability of preparing extracts and investigating the structures of novel compounds. This enables them to add maximum value to their natural products within their own country. The few developing countries which have reached this stage did so not with patent protection, but by locally produced technology and adaptive innovation (WRI, 1992).70 Many industrialized countries have followed the same path, avoiding the strict patent protection that can stop low-cost imitations. France, for example, only began to grant patents for pharmaceuticals in 1958, Japan in 1976, and Switzerland in 1977 (Lesser, 1991).44 In developing countries or regions where sufficient expertise has been developed, researchers can prepare extracts and take the search for new industrial products as far as possible before settling on an international partnership agreement when additional technology is required. For countries not yet at this stage, or where screening and development of new drugs is too costly, royalties need to be negotiated with large companies, respecting minimum standards (Box 4).

3.. CASE STUDY: BELIZE ETHNOBOTANY PROJECT*

This project is aimed at the long-term study of forest plant uses, concentrating on collecting, documenting, and preserving local knowledge of plant use. It started in 1987 through collaborative work between the New York Botanical Garden and residents of Belize working with herbal medicines (medical doctors and curanderos). Set up with support from US-AID, the USA National Cancer Institute (NCI) and several foundations, it is run in collaboration with the Belize Ministry of Health, the Departments of Archaeology and Forestry, and the Belize Centre for Environmental Studies.

A very important aspect of the Belize Ethnobotany Project is the objective evaluation of random screening for active ingredients based on ethnobotanical uses and traditional knowledge. Screening is being done by the NCI, with a focus on screening for anti-HIV activity. At the end of a five-year period, information on 7,500 plant samples, representing 2,000-4,000 species will be available, enabling detailed comparison of active ingredients by plant family, and the «hit» rate achieved with random screening versus screening based on traditional knowledge.

Early indications, based on a small sample, are that a higher "hit" rate has been achieved with plants collected because of a reported therapeutic value compared with those collected randomly.

Collection Method

  Random Collection Ethnobotanical Collections
Total species tested 18 20
Number active (per cent) 1 (6%) 5 (25%)

Michael Balick, Director of Economic Botany at the New York Botanical Garden writes, «The lull in natural-products research over the last few decades combined with the reduction in global plant biodiversity has resulted in an urgent race against time. Given the relatively small number of scientists qualified to address the problem, it is clear that choices in the allocation of time and resources must be made. The ethno-directed sampling methodology allows the researcher to obtain a higher number of leads in a pool of plant samples compared to a group of plants selected at random. Broader utilization of this methodology could streamline the discovery and development of drugs from natural products."

*Balick, 1990, 19917,8

 
4. CONTRACT GUIDELINES

These guidelines were developed at the ASOMPS VII meeting in Manila, Philippines, in February, 1992. They recognize that there is considerable variation in the levels of technical expertise in different Asian countries relating to investigation of new natural products. In the absence of sufficient expertise to undertake screening within the country, it has been suggested that, in the short term, efficient development of new natural products may involve sharing of biological resources and technology between countries of origin of biological material and developed countries. The following minimum standards were suggested in the Manila Declaration (Appendix 2):

  1. The amount of material collected for initial screening should not normally exceed 100-500 grams (dry weight) unless specific permission is obtained.
  2. Payment should include all handling expenses.
  3. Where screening is carried out with the aid of a partner organization in the developed world, a minimum of 60 per cent of any income arising from the supply of extracts to commercial organizations should be returned to the appropriate country organization.
  4. The country organization should receive a minimum of 51 per cent of any royalties arising from external collaboration that result in marketable products. As fair royalties are normally 3-5 per cent, the national organization would expect to receive a minimum royalty of 1.5-2.5 per cent.
  5. The country, organization should not sign agreements that give exclusive, indefinite rights to any external party. Exclusivity should be limited to no more than a two-year period.
  6. Complete evaluation results should be reported to the supplying country within 6-9 months.
  7. If there is a threat of destructive harvesting, costs of sustainable harvesting or the development of alternative supplies must be borne by the external organization.
  8. The contribution of research participants should be recognized through co-authorship of publications (unless anonymity has been requested).
  9. Where possible, screening of extracts should be carried out in the country of origin, and assistance should be provided to develop this expertise wherever possible.

 

4.1.5 Policy and professional approaches

In contrast to the disputes that occurred over recognition of farmers' rights, many professional organizations have expressed their support for equitable partnerships and sustainable use of resources in the development of new natural products (Table 5). Most of these have been broad policy statements. In 1987, the IUCN Working Group on Traditional Ecological Knowledge drew attention to the value of indigenous knowledge, and stressed the need for equitable partnerships involving anthropologists, ecologists, and indigenous peoples. The following year, the International Society of Ethnobiology (ISE) (Box 5) called for mechanisms to be established which recognized and compensated indigenous peoples for the use of specialist knowledge (Posey, 1990; Boom, 1990).56,11 Other examples are the Chiang Mai Declaration for Conservation of Medicinal Plants (WWF/IUCN/WHO) and the 1989 Goteburg Resolution of the International Society of Chemical Ecology, which urged the development of partnerships between developed and developing nations and a great increase in screening for new compounds (Eisner and Meinwald, 1990).25

In 1990, the Botanical Society of America (BSA) and the Society for Economic Botany (SEB) established ethics committees which aimed to develop professional codes for these organizations (Boom, 1990; D. Harder, pers comm., 1991).11 Very useful guidelines were also produced at a workshop held by the NCI at Bethesda (Schweitzer et al., 1991)63 (Box 6). Two significant events in 1992 were the Williamsburg Declaration by the American Society of Pharmacognosy, and the Bukittinggi Declaration at the UNESCO seminar on the Chemistry of Rainforest Plants, held in West Sumatra, Indonesia. Also in 1992, the Global Biodiversity Strategy (WRI, 1992)70 called for coordinated action to:

  • assert national sovereignty over genetic resources and regulate their collection
  • recognize and quantify the local economic value of wild plant products harvested sustainably
  • encourage local communities to obtain a larger market share for wild products harvested sustainably
  • develop the role of traditional medicines in local healthcare programmes, and ensure their appropriate and sustainable use
  • promote recognition of the value of local knowledge and genetic resources, and affirm the rights of local peoples
  • base the collection of genetic resources on contractual or other agreements that ensure
  • equitable returns.

Table 5. Summary of issues relating to new natural products development covered in resolutions or statements of various organizations.

Organization

Equitable Partnerships

Training/ Technology Transfer

Health in Developing Countries

Sustainable Resource Use

Survey Species & Traditional Knowledge

National Sovereignty

International Society of Ethnobiology

*

*

*

*

*

*

International Society of Chemical Ecology (1989)

*

   

*

*

 
Society of Economic Botany (1991)

*

*

*

*

*

 
NIH/NCI workshop of Drug Development, Biological Diversity & Economic Growth (1991)

*

*

*

*

*

 
Global Biodiversity Strategy (WRI/IUCN and UNEP) (1992)

*

*

*

*

*

*

ASOMPS (Asian Symposium for Medicinal Plants, Spices and other natural products (1992

*

*

*

*

*

*

American Society of Pharmacognosy (1992)

*

*

*

*

*

*

From Posey, 1991; 58Einser, and Meinwald, 1990;25 Schweitzer et al.,1991;63 Padoch and Boom,1991;53 WKI,1992;70 Cruz et al., 1992.17

Some pharmaceutical companies have also set out their policies for acquisition of plant materials in the search for active ingredients. Glaxo Group Research Ltd, for example, will only conclude agreements with bona fide organizations rather than with individuals. They also specify that they will cover costs of supply and recognize the negative effects that unauthorized removal of material can have on the environment and economies of the countries concerned, particularly in the developing world (Glaxo, 1992).30

The 1992 Manila Declaration, concerning the ethical utilization of Asian biological resources, is a notable exception to most policy statements. In addition to setting out policy guidelines, the Manila Declaration gives a clear and concise code of ethics for foreign-collectors of biological samples and a set of minimum contract guidelines (Cruz et al., 1992).17 The Declaration has recently been published as a booklet by the Regional Network for the Chemistry of Natural Products of Southeast Asia (1993).

Some contracts already exist, such as that of the American National Cancer Institute «Letter of Intent» (NCI, 1992),51 the more specific University of Strathclyde agreement for supply of plant material (P. Waterman, pers comm., 1992) and a draft agreement developed by the Rainforest Alliance (Carney et al., 1992).13 The philosophy and guidelines contained in the Manila Declaration are significant because they demonstrate a high degree of consensus among natural products chemists from a range of developing countries (Boxes 7, 4).

4.1.6 Dealing with unrecorded knowledge

It is important that a distinction be made between the ethics associated with indigenous knowledge that is already published and in the public domain, and the ethics involved in soliciting and recording previously unrecorded knowledge (T. Johns, pers comm., 1993). In the former case, guidelines regarding this information would best apply at a national level governing the collection and utilization of biological samples concerned.

5. DECLARATION OF BELEM

Leading anthropologists, chemists, sociologists, and representatives of several indigenous populations met at First International Congress of Ethnobiology, in Belem, Brazil. Their aim was to discuss common concerns and to found the International Society of Ethnobiology. Major concerns outlined by conference contributors were to study the ways that indigenous and peasant populations uniquely perceive, utilize, and manage their natural resources, and to develop programmes that will guarantee the preservation of vital biological and cultural diversity. They made the following declaration:

As ethnobiologists, we are alarmed that:

SINCE

  • tropical forests and other fragile ecosystems are disappearing
  • many species, both plant and animal, are threatened with extinction
  • indigenous cultures around the world are being disrupted and destroyed

and GIVEN that

  • economic, agricultural, and health conditions of people are dependent on these resources
  • native peoples have been stewards of 99 per cent of the world' s genetic resources
  • there is an inextricable link between cultural and biological diversity

THEREFORE, as members of the International Society of Ethnobiology, we strongly urge action as

follows:

  1. Henceforth, a substantial proportion of development aid be devoted to efforts aimed at ethnobiological inventory, conservation, and management programmes.
  2. Mechanisms be established by which indigenous specialists are recognized as proper authorities and are consulted in all programmes affecting them, their resources, and their environments.
  3. All other inalienable human rights be recognized and guaranteed, including linguistic identity.
  4. Procedures be developed to compensate native peoples for the utilization of their knowledge and their biological resources.
  5. Educational programmes be implemented to alert the global community to the value of ethnobiological knowledge for human wellbeing.
  6. All medical programmes include the recognition of and respect for traditional healers, and the incorporation of traditional health practices that improve the level of health of these populations.
  7. Ethnobiologists make available the results of their research to the native peoples with whom they have worked, especially including dissemination in the native language.

Exchange of information be promoted among indigenous and peasant peoples regarding conservation, management, and sustained utilization of resources.

By contrast, the solicitation of previously unrecorded knowledge is best approached through participatory research at a local community level, from the bottom up. This approach is more likely to provide a means for the people whose knowledge is sought: (i) to come to agreement with the researcher on research goals and feedback of information to the community; (ii) to set any limitations on the type of information to be disseminated; (iii) to come to agreement on reasonable compensation; and/or (iv) to refuse to participate.

The ethics of interaction between researchers and the people who are the source of traditional knowledge is not only a responsibility of the individual researcher and the organization and/or professional society to which the researcher belongs, but also of national governments. Although the definition of local communities and indigenous peoples can vary widely, the ethics and rules for people undertaking ethnobiological surveys or collecting samples for new natural products development should be the same for foreigners as for nationals from outside those communities.

6. CONCLUSIONS OF THE WORKSHOP ON "DRUG DEVELOPMENT, BIOLOGICAL DIVERSITY AND ECONOMIC GROWTH"

held by the NlH/National Cancer Institute (NCI) at Bethesda, Maryland, March 1991 *

General Principles

  1. Equal partnership, cooperation, and fair compensation are the principles which should guide all multinational efforts to maintain and sustainably use biodiversity and traditional knowledge.
  2. The maintenance of biological and traditional knowledge can be viable only if it makes economic sense in the cultural, political, and developmental situation of the countries concerned. Special attention needs to be given to maintaining biological diversity in areas where other natural resources are being used.
  3. Traditional knowledge is as threatened and is as valuable as biological diversity. Both resources deserve respect and must be conserved.
  4. Traditional healers and indigenous peoples have valuable knowledge and important observations and analytical capabilities. These specialists may know almost all of the useful and medicinal plants available in the ecosystem.
  5. Efforts to develop drugs from medicinal plants should address disease and health problems seen in developing countries as well as diseases which primarily affect developed countries' populations.

Compensation and Intellectual Property Rights

  1. Intellectual property rights should be extended in some form to traditional knowledge, and mechanisms to provide appropriate protection and compensation are urgently needed.
  2. Compensation for traditional knowledge need not always be in the form of cash, although financial compensation is important. Other forms of compensation could include technology transfer, training, resource maintenance, and institutional development.
  3. Multinational corporations, anthropologists, botanists, and others involved in the use of natural products and traditional knowledge need to recognize their responsibility to provide reasonable compensation as an integral part of their business or research and development activities.
  4. Intermediate compensation mechanisms and incentives need to be developed to bridge the 10-15 years that may elapse between the identification of a potentially useful species and the production of a marketable and profitable drug from that species.

Training, Institution Building, and Information Transfer

  1. Enhancing capabilities for conservation and sustainable use of resources through training should be a high priority. Any such training efforts should recognize and use local knowledge and capabilities, especially in relation to resource management and raw-material processing.
  2. Countries have varying capabilities to exploit and sustain their biological diversity and traditional knowledge resources. There are, therefore, different needs for external assistance and cooperation. In all cases, any existing indigenous capabilities should be strengthened so that solutions are developed which account for each developing country's unique circumstances.
  3. Appropriate conservation and resource-exploitation technologies and knowledge need to be transferred to developing countries. This should be done through training, joint research, and other activities in resource cataloguing, monitoring, and use. Countries that are rich in biological resources can often learn from each other's experience to develop solutions suited to their circumstances.
  4. Efforts to educate the public and decision-makers are critically important to ensure broad and effective recognition of biological diversity and traditional knowledge in conservation and development
  5. An immediate priority is the completion of species and traditional-knowledge inventories, which should include information dissemination. These inventories need to be developed using electronic databases with wide access.
  1. Some countries need to further develop their traditional medicine quality-control mechanisms and national capabilities to manage systems of production and distribution of traditional medicines.

* Schweitzer et al.; 199163

 
7. CODE OF ETHICS FOR FOREIGN COLLECTORS OF BIOLOGICAL SAMPLES

The reference document was developed at the Botany 2000 Herbarium Curation Workshop held in Perth, Western Australia, in October 1990. It was modified in April 1992 to cover other biological material and formed Appendix 1 to the Manila Declaration (1992).

The foreign collector should:

  1. Arrange to work with a local scientist(s) and institute(s).
  2. Respect regulations of the host country; for example, by entering on a research/collecting visitor visa, not a tourist visa, and observe regulations for export of biological specimens, quarantine, CITES, etc.
  3. Obtain official permission for all collecting in National Parks or protected areas.
  4. Ascertain whether items used in scientific work and which are difficult to obtain can be contributed.
  5. When applying for a travel study grant, include equal travel expenses for local counterpart(s) and an amount to cover the cost of processing museum specimens or other costs of the visit to the host institute.
  6. Leave a complete set of adequately labeled duplicates with the institute before departing the country.
  7. Ensure that types of species described as a result of the research are deposited in the National Museum or Herbarium of the country of origin.
  8. Inform the institute in the country of origin where duplicate specimens are to be deposited.
  9. Not exploit the natural resources of the host country by removing high-value biological products; for example, collecting without prior permission plants with potential horticultural, medicinal, cultural, or other economic value.
  10. Obtain a list of rare and endangered species of the country visited and not collect these species without permission.
  11. Collect no more material than is strictly necessary; collect cuttings or seeds for live plant specimens, rather than uprooting whole plants; collect subsections rather than whole organisms, wherever possible, for marine specimens.
  12. Leave photographs/slides for the host institute(s).
  13. Inform the host institute or appropriate organization of the whereabouts of any rare or endangered species that are found.
  14. Send copies of research reports and publications to collaborator(s) and host institute(s).
  15. Acknowledge collaborator(s) and host institute(s) in research reports and publications.
  16. Collect identified reference voucher specimens for all biological products to be exported.

4.2. Conservation and Biodiversity

Despite concerns about the emphasis on economic and utilitarian values, economic reasons remain powerful arguments for conservation (McNeely, 1988).49 Under the «common property system» that considers genes or chemical structures from biological material as the common heritage of mankind, there is little incentive to conserve either species or habitats. «Chemical prospecting», as Eisner calls it, can be a powerful ally that is compatible with biological conservation. This will only occur, however, if a fair share of benefits reverts to the region of origin. National sovereignty over renewable resources such as timber, rattan, or latex has long been recognized. The same applies to non-renewable resources such as oil, gold, or other minerals. Why shouldn't national sovereignty also apply to chemical structures from plants, or to plants with horticultural value? Sales of the African violet (Saintpaulia), for example, are worth $30 million a year (Lovett, 1988),45 but none of this money is used to conserve the Tanzanian habitat they originally came from.

The same applies to the monetary and non-monetary benefits from industrial products developed from biological material, such as drugs, resins, waxes, oils, and perfumes. The question might be asked, «What if the source material came from Switzerland, rather than Tanzania or another developing country?» Would the same situation be tolerated? The issue does not arise because, while Switzerland, France, Germany, and the UK all have companies involved in drug development, they are a poor source of biological material. Compare, for instance, the number of endemic plant species in Switzerland (1), Germany (73), or the United Kingdom (16 ) with countries or regions where chemical prospecting is taking place, such as Mexico (3376) or the Amazon region (25,000-30,000).

Unfortunately, the products of biological and cultural diversity are undervalued. There are two main reasons for forest overexploitation and destruction under these circumstances (Repetto, 1989).60 First, forests have been undervalued and thus misused. A few products such as hardwoods and rattans, have been exploited but other resources, such as nuts, oils, and fibres, have been overlooked. At the same time, important features like watersheds have been ignored. Second, the net benefits from forest exploitation and conversion have been overestimated. For example, Repetto states that plans to harvest tropical timber every 35 years in clear-cut stands are «grossly unfulfilled» in Indonesia, the Philippines, and elsewhere. To offset this, the benefits derived from chemical and genetic material can enhance values from more tangible «minor forest products».

These forests have a high level of endemism, and contain many medicinal plants with potential value in new natural products development, e.g. members of the Ancistrocladaceae, Oknemataceae and Clusiaceae. If governments fail to appreciate the value of biodiversity, development that destroys this resource continues unhindered.

4.2.1 Different forests, different values

Recent studies have suggested that rainforest preservation in the Peruvian Amazon (Peters et al., 1989),55 and Southeast Asia (de Beer and McDermott, 1989),23 can sometimes be justified through direct contribution of forest products to the local economy. For example, an estimate was made of the production and market value of all commercial tree species (whether fruits, latex, or timber) in a 1ha Amazonian rainforest in Peru (50 families, 275 species 10 cm diameter). Of the total number of trees on the site, only 72 species (26.2 per cent) yielded products with an actual market value. The financial appraisal concluded that total net revenues of «minor» forest products, collected sustainably and sold in the Iquitos market, were two to three times higher than those arising from forest conversion. Based on the assumption of sustainable collecting, the study estimated that harvests of fruit and latex alone were worth about $6,330/ha/yr, provided that 25 per cent of the fruit crop was left in the forest for regeneration. This can be compared with $3,184/ ha/yr for Gmelina arborea pulpwood plantations, $490 for timber from the forest, and $148/ha/yr from cattle pastures in Brazil.

The value of non-timber forest products may not always be so high. The economic value of a forest obviously depends on the availability of markets and the diversity and yield of economically important products. Studies made in primary lowland rainforest in peninsular Malaysia (Saw et al., 1991),62 for example, reached a very different conclusion to those in the Peruvian Amazon. Despite its diversity (820 species in a 50ha plot), only one species, Parkia speciosa, was regularly gathered for sale, with the total contribution to the local economy estimated at $20/ha/yr, compared to the $6,330/ha/yr recorded in Peru. This study suggests that de Beer and McDermott's proposal be viewed with caution. The same could apply to the broader application of the work by Peters et al. Both cases emphasize the importance of future «option values» as potential new industrial products are discovered or genetic material for plant breeding is removed.

Figure 5. The beginning of the end: from diversity to monoculture of oil palm or rubber as a new road is pushed through lowland rainforest in Côte d'Ivoire, West Africa. Photo: A B Cunningham
The Malaysian lowland forest which was studied proved to be exceptionally rich as a genetic reservoir for fruit trees, particularly Garcinia (Clusiaceae, mangosteens), Artocarpus (Moraceae,breadfruit) and Nephelium (Sapindaceae, rambutan, or litchi). Twenty-four species in the forest were cultivated elsewhere, 38 species were congeneric with cultivated crops, and at least 10 species were closely related to edible fruit-bearing crops. Many more may have potential value as new drugs. Constructive partnerships between local people, national researchers, and internationally-based chemists and drug companies can stimulate the discovery of new natural products. This could have a tremendous «value added» effect.

The development of pharmaceutical industries in India and Brazil, and the well-publicized contract between Merck, Sharpe, and Dohme and Costa Rica's National Institute for Biodiversity (INBio) (Joyce, 1991),39 are examples of partnerships are not developed, then this approach (Box 8). If effective partnerships are not developed, then tropical forest conservation will have to rely on other funding mechanisms, such as «debt-for-nature» swaps, and on international support.

CASE STUDY: INSTITUTO NACIONAL DE BIODIVERSIDAD (INBio), COSTA RICA*

Founded in 1989, the National Biodiversity Institute (INBio) has been recognized worldwide for its innovative approaches to linking new natural products development, inventories, and conservation. As director Rodrigo Gamez says: «We want to put our biodiversity to work for us. But we want to be perceived as partners, not as a resource to be exploited. We will have absolute control over who will be allowed to operate in protected areas." Biologists are required to get permits and deliver samples of everything they collect to INBio. Any profit made must be shared with Costa Rica.

In October 1991, Merck Pharmaceuticals contracted to pay INBio $1 million for the opportunity to screen samples that INBio is collecting, with patent rights retained by Merck, but with INBio receiving an undisclosed royalty (thought to be 1-3 per cent) if marketable products are discovered. Ten per cent of the up front money and 50 per cent of Costa Rica's share of any royalties will be invested in conservation in Costa Rica through a special fund managed in agreement with the government.

In addition, INBio draws on the expertise of local people trained as "parataxonomists" as well as professional biologists from the University of Pennsylvania (USA), the Natural History Museum (UK), Missouri Botanical Garden (USA), and the US Department of Agriculture/Smithsonian Institution (USA). It has signed cooperative agreements to undertake an inventory of all species in Costa Rica. Indonesia and Brazil have reportedly expressed interest in similar agreements.

* Joyce, 1991;39 WR1, 1992;70 Stone, 1992


5. Wild Harvesting, Herbal Preparations, and Extracts

In the large majority of cases, companies investigating natural products work with small quantities of plant material. They are looking for specific active compounds that may lead to new drugs which are likely to be synthesized chemically. Sometimes, however, large quantities are required from wild collections or from cultivation. This is the case when synthesis poses a problem, as with the anti-cancer agent taxol, derived from the bark of the Pacific yew, Taxus brevifolia (Hamburger et al., 1991).33 It is also the case when treatments use herbal extracts, as in herbal and traditional medicines, or where whole extracts are required. Finally, it is the case when, although synthesis or cultivation is possible, harvesting material from the wild is cheaper.

The international trade in leaf extract of Ginkgo biloba was valued at $500 million a year (Corey et al., 1988),16 requiring about 100 tonnes of dried leaves per month for extraction (Balz, 1988).9 These leaves are primarily from cultivated plantations in France and the USA, rather than from destructive harvesting. This is not the case however, with trade from or within many developing countries. According to the UNCTAD/GATT International Trade Centre, the total value of imports of medicinal plants to OECD countries, Japan, and the USA increased from $335 million in 1976 to $551 million in 1980 (Husain, 1991).37 Unfortunately, the low prices paid for the plants do not cover replacement or resource management costs. This means that major importers who demand high volumes of plant material are effectively contributing to the decline of medicinal plant species.

Even when the technology for chemical synthesis is available, it can be cheaper for pharmaceutical companies to continue to extract the active ingredients from the plants. In the mid-1970s, for example, synthesis of reserpine cost $1.25/g, compared to $0.75/g for commercial extraction from the roots of Rauwolfia vomitoria (Oldfield, 1984).52

Other examples include the processing of 75-80 tonnes of Griffonia simplicifolia seed exported every year to Germany from Ghana (Abbiw, 1990),1 and the medicinal plant material exported from Cameroon to France (Cunningham and Mbenkum, 1993).20 In 1985-1991, this amounted to 900 tonnes of Voacanga africana seed, 11,537 tonnes of Prunus africana bark for an extract used to treat prostatitis in Europe, and 286 tonnes of Pausinystalia johimbe bark to be sold as an aphrodisiac in sex shops.

With few exceptions, prices paid to gatherers are very low, and bear no relation to annual sustainable off-take. In many cases, the wild plants are also treated as resources available to anybody without controls. To make a living, commercial medicinal plant gatherers are forced to «mine» rather than manage these resources.

Figure 6. Traditional Chinese medicines on sale in Yunnan province, China. Photo: A B Cunningham
If the international companies involved in this trade are to operate in a responsible marnner, this situation needs to change to one of two alternatives: commercial cultivation or sustainable gathering from the wild. If Beafour Laboratories (France) are prepared to establish their own plantations of some 15 million Ginkgo biloba (Gingoaceae) trees in France and the USA (Balz, 1988),9 why shouldn't Laboratoires Debat cultivate Prunus africana in Cameroon, instead of buying and processing bark that is destructively harvested from declining areas of the Afro-montane forest?

6. Expectations and Economic Benefits

It is important that participants in source countries do not develop unrealistic expectations about the benefits that may arise from the development of valuable new products. These benefits include both short-term payments for samples and the kind of non-monetary benefits outlined above. Only a small percentage of active ingredients lead to new pharmaceuticals: «hit» rates are between 1:6,000 and 1:10,000. Over a 25-year period, for example, Merck, Sharp, and Dohme found only five compounds that, either directly or with some chemical modification, have become marketable drugs (Schweitzer et al., 1991).63 Development costs are high and, although patent rights generally last up to 20 years, 10-15 years of this may be taken up in drug development before marketing can take place.

The cost of new drug development in 1986 was estimated as $50-100 million per product (Tyler, 1986).65 Today, a realistic estimate would be closer to $200 million per product, if the cost of failures is taken into account. For this reason, it is important that collectors, researchers, or sponsoring organizations do not give misleading information regarding the possible commercial benefits of the research.

However, it is true that when a «hit» is made, the profits can be very large. One well-publicized example is the anti-leukaemia drugs developed from Catharanthus roseus, which were patented and marketed in 1963, with sales of approximately $100 million by 1985, 88 per cent of which was profit (Farnsworth, 1988).28

 
| ResourcesAbout Us  |  What's New  |  Notice Board Opinion  |  FAQ   |  Archive  |  Feedback  |  Main  |
WWF Logo Unesco Logo Kew Logo
People and Plants Online website manager: Gary J. Martin,B.P. 262, 40008 Marrakech-Medina, Marrakech, Morocco;
Fax +212.4.329544, e-mail
peopleandplants@cybernet.net.ma
Website design & maintenance by
RAM Production Sdn. Bhd.
People and Plants Online © WWF, UNESCO and Royal Botanic Gardens, Kew
Disclaimer
Links to other websites cited in People and Plants Online do not imply endorsement of these sites or their content
by the People and Plants Initiative or its sponsoring institutions